We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
FRSOB | Forrestania Resources Ltd | 0.01 | 0.008 | 400.00% | 9,585,871 | 43 |
FRSOA | Forrestania Resources Ltd | 0.006 | 0.004 | 200.00% | 4,322,578 | 36 |
CAQ | CAQ Holdings Limited | 0.071 | 0.044 | 162.96% | 568,946 | 17 |
AS2O | Askari Metals Ltd | 0.005 | 0.003 | 150.00% | 15,000 | 1 |
FRS | Forrestania Resources Ltd | 0.045 | 0.026 | 136.84% | 78,642,571 | 1,764 |
TMKOB | TMK Energy Ltd | 0.002 | 0.001 | 100.00% | 2,794,436 | 4 |
AUNOC | Aurumin Limited | 0.002 | 0.001 | 100.00% | 11,671,509 | 18 |
AUZOB | Australian Mines Ltd | 0.002 | 0.001 | 100.00% | 2,026,413 | 5 |
BRXOA | Belararox Ltd | 0.065 | 0.024 | 58.54% | 10,000 | 1 |
MTMO | MTM Critical Metals Ltd | 0.003 | 0.001 | 50.00% | 500,000 | 1 |
VPR | Volt Power Group Limited | 0.0015 | 0.0005 | 50.00% | 601,419 | 13 |
—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance on Multiple Secondary Endpoints for Both Dosage Strengths Versus Placebo— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results from ASPEN Validate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at 8:00 am ET on Tuesday, May 28, 2024— BRIDGEWATER, ...
STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares ("ADS") of Calliditas Therapeutics AB (publ) (jointly the "Securityholders") accept the public tender offer by Asahi Kasei Corporation.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to treat CF, at the 47th European Cystic Fibrosis Conference on June 7, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 68,444.43 | -948.76 | -1.37% | 1.34T | 3,934,494,484 |
ETH | Ethereum | 3,901.80 | 10.19 | 0.26% | 468.11B | 2,921,527,638 |
USDT | Tether USD | 0.99899 | -0.0002 | -0.02% | 97.74B | 148,254,833 |
BNB | Binance Coin | 602.20 | -1.21 | -0.20% | 95.02B | 220,062,468 |
SOL | Solana | 170.93 | 0.880 | 0.52% | 75.01B | 965,898,121 |
STETH | stETH | 3,899.50 | 8.67 | 0.22% | 38.21B | 9,613,362 |
XRP | Ripple | 0.5302 | -0.0035 | -0.66% | 28.9B | 255,277,472 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 849,404,440 |
DOGE | Dogecoin | 0.16567 | -0.00339 | -2.01% | 23.7B | 473,505,214 |
TONCOIN | Wrapped TON Coin | 6.40 | -0.129254 | -1.98% | 22.18B | 49,721,419 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions